Evidence map›Paper›PMID 34259648›Full record

ArticleEndocrine connections2021

Mapping the journey of transition: a single-center study of 170 childhood-onset GH deficiency patients.

Mirjana Doknic, Marko Stojanovic, Ivan Soldatovic, Tatjana Milenkovic, Vera Zdravkovic, Maja Jesic, Sladjana Todorovic, Katarina Mitrovic, Rade Vukovic, Dragana Miljic and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine connections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. [Management of transition growth hormone deficiency].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Mirjana DoknicNeuroendocrine Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Belgrade, Serbia.
Marko StojanovicNeuroendocrine Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Belgrade, Serbia.
Ivan SoldatovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Tatjana MilenkovicMother and Child Health Care Institute of Serbia 'Dr Vukan Cupic', Belgrade, Serbia.
Vera ZdravkovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Maja JesicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Sladjana TodorovicMother and Child Health Care Institute of Serbia 'Dr Vukan Cupic', Belgrade, Serbia.
Katarina MitrovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Rade VukovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.ORCID 0000-0002-1592-4105
Dragana MiljicNeuroendocrine Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Belgrade, Serbia.
Dragan SavicClinic for Neurosurgery, University Clinical Center of Serbia, Belgrade, Serbia.
Mihajlo MilicevicClinic for Neurosurgery, University Clinical Center of Serbia, Belgrade, Serbia.
Aleksandar StanimirovicClinic for Neurosurgery, University Clinical Center of Serbia, Belgrade, Serbia.
Vojislav BogosavljevicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Sandra PekicNeuroendocrine Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Belgrade, Serbia.
Emilija Manojlovic-GacicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Aleksandar DjukicDepartment of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Danica GrujicicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Milan PetakovNeuroendocrine Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Belgrade, Serbia.
University of Belgrade · RSCentar za Promociju Nauke · RSInstitute of Public Health of Serbia · RSInstitute of Criminological & Sociological Research · RSUniversity Children's Hospital, Belgrade · RSUniversity of Kragujevac · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo analyze metabolic parameters, body composition (BC), and bone mineral density (BMD) in childhood-onset GH deficiency (COGHD) patients during the transition period (TP).

designSingle- center, retrospective study was performed on 170 consecutive COGHD patients (age 19.2 ± 2.0 years, range 16-25) transferred after growth completion from two pediatric clinics to the adult endocrine unit. Two separate analyses were performed: (i) cross-sectional analysis of hormonal status, metabolic parameters, BC, and BMD at first evaluation after transfer from pediatrics to the adult department; (ii) longitudinal analysis of BC and BMD dynamics after 3 years of GH replacement therapy (rhGH) in TP.

resultsCOGHD was of a congenital cause (CONG) in 50.6% subjects, tumor-related (TUMC) in 23.5%, and idiopathic (IDOP) in 25.9%. TUMC patients had increased insulin and lipids levels (P < 0.01) and lower Z score at L-spine (P < 0.05) compared to CONG and IDOP groups. Patients treated with rhGH in childhood demonstrated lower fat mass and increased BMD compared to the rhGH-untreated group (P < 0.01). Three years of rhGH after growth completion resulted in a significant increase in lean body mass (12.1%) and BMD at L-spine (6.9%), parallel with a decrease in FM (5.2%).

conclusionThe effect of rhGH in childhood is invaluable for metabolic status, BC, and BMD in transition to adulthood. Tumor-related COGHD subjects are at higher risk for metabolic abnormalities, alteration of body composition, and decreased BMD, compared to those with COGHD of other causes. Continuation of rhGH in transition is important for improving BC and BMD in patients with persistent COGHD.

Indexed as

body compositionbone mineral densityCOGHDmetabolismtransition period

Identifiers

PMID34259648
PMCPMC8428021
OpenAlexW3181218371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.